# A Phase I/III Clinical Study to Evaluate NouvNeu001 Injection for Multiple System Atrophy

> **NCT07289477** · PHASE1 · RECRUITING · sponsor: **iRegene Therapeutics Co., Ltd.** · enrollment: 9 (estimated)

## Conditions studied

- Multiple System Atrophy - Parkinsonian Subtype (MSA-P)

## Interventions

- **BIOLOGICAL:** Human Dopaminergic Progenitor Cells

## Key facts

- **NCT ID:** NCT07289477
- **Lead sponsor:** iRegene Therapeutics Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-01-05
- **Primary completion:** 2027-10
- **Final completion:** 2031-07
- **Target enrollment:** 9 (ESTIMATED)
- **Last updated:** 2026-04-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07289477

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07289477, "A Phase I/III Clinical Study to Evaluate NouvNeu001 Injection for Multiple System Atrophy". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07289477. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*